EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
11.01
+0.26 (2.42%)
At close: Aug 13, 2025, 4:00 PM
11.20
+0.19 (1.72%)
Pre-market: Aug 14, 2025, 8:05 AM EDT
EyePoint Pharmaceuticals Revenue
EyePoint Pharmaceuticals had revenue of $5.33M in the quarter ending June 30, 2025, a decrease of -43.73%. This brings the company's revenue in the last twelve months to $51.90M, up 2.99% year-over-year. In the year 2024, EyePoint Pharmaceuticals had annual revenue of $43.27M, down -5.97%.
Revenue (ttm)
$51.90M
Revenue Growth
+2.99%
P/S Ratio
13.72
Revenue / Employee
$314,533
Employees
165
Market Cap
758.89M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EYPT News
- 7 days ago - EyePoint Pharmaceuticals, Inc. (EYPT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 8 days ago - EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 15 days ago - EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 16 days ago - EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - GlobeNewsWire
- 4 weeks ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026 - Seeking Alpha
- 2 months ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire